Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer

UVA Tracking #
HSR200444
Principal Investigator
Linda R Duska
Contact
Linda Duska
Contact Phone
434.924.5100
Official Trial Title
Phase 1b/2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have platinum sensitive recurrent ovarian cancer. If you join this study, you will receive a combination of two drugs: oregovomab and niraparib. The purpose of this study is to help answer the following research question(s):
• Is the combination of oregovomab and niraparib safe? Are there any side effects that might be associated with the drug combination?
• How do these two drugs interact with your cancer and your body?
• Does the combination of oregovomab and niraparib cause a response from your immune system?
• Does the combination treat your cancer?

Recruitment and treatment with the study medication is expected to last up to approximately 24 weeks. After stopping taking the study drug, your Study Doctor will check on you every 3 months for 1 year stopping after treatment. This means you could keep seeing the Study Doctor on this study for up to 2 years after stopping the study drug.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. You will be reimbursed up to $117.19 per visit for your travel expenses.

There is no assurance that participating in the study will benefit you in any way. The study provides an opportunity to delay your next line of chemotherapy and prolong the platinum free window. Participants in the study will contribute to the understanding of interactions between Oregovomab and Nirparib that will better serve our understanding of how to treat future patients.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05335993

Compensation

No Compensation